Olympus VE2 NIR Imaging System for Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Massachusetts General Hospital, Boston, MA
Lung Cancer+1 More
Olympus VE2 NIR Imaging System - Device
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This will be a prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy and pulmonary segmentectomy. The aims of the study are: 1. To utilize NIR intraoperative imaging with the Olympus VE2 NIR Imaging System to: i. Characterize gastric conduit perfusion during esophagectomy and, ii. Identify segmental anatomy during sublobar pulmonary resection (segmentectomy) after intraoperative, intravenous delivery of low-dose 0.15 mg/kg of ICG.

Eligible Conditions

  • Lung Cancer
  • oesophageal lesion

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: During surgery

During surgery
To utilize NIR intraoperative imaging with the Olympus VE2 NIR Imaging System for esophagectomy patients.
To utilize NIR intraoperative imaging with the Olympus VE2 NIR Imaging System for segmentectomy patients.

Trial Safety

Trial Design

2 Treatment Groups

During Minimally Invasive Esophagectomy (Group 1)
1 of 2
During Minimally Invasive Pulmonary Segmentectomy (Group 2)
1 of 2
Experimental Treatment

45 Total Participants · 2 Treatment Groups

Primary Treatment: Olympus VE2 NIR Imaging System · No Placebo Group · Phase 1 & 2

During Minimally Invasive Esophagectomy (Group 1)Experimental Group · 2 Interventions: Indocyanine green, Olympus VE2 NIR Imaging System · Intervention Types: Drug, Device
During Minimally Invasive Pulmonary Segmentectomy (Group 2)Experimental Group · 2 Interventions: Indocyanine green, Olympus VE2 NIR Imaging System · Intervention Types: Drug, Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Indocyanine green
2016
Completed Phase 3
~590

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: during surgery

Trial Background

Christopher R. Morse M.D., MD
Principal Investigator
Massachusetts General Hospital
Closest Location: Massachusetts General Hospital · Boston, MA
Photo of Massachusetts General Hospital  1Photo of Massachusetts General Hospital  2Photo of Massachusetts General Hospital  3
1993First Recorded Clinical Trial
0 TrialsResearching Lung Cancer
2425 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.